MANCHESTER, Conn., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a division of Lydall, Inc., (LDL) announced today that it has recently launched the new EXP-Pak(TM) cell expansion containers intended for the expansion and culture of non-adherent cells. The launch of this exciting new product family allows Charter Medical to provide enabling technology critical to the rapidly growing cellular therapy market. The family of closed-system cell expansion containers offers a broad size range from 500mL to 5L and end-user validated cell expansion rates and recovery.

Joe Petrosky, Vice President of Global Marketing and Sales for Charter Medical, stated, "We are excited with the launch of the EXP-Pak(TM) cell expansion product family. The EXP-Pak(TM) containers complement our closed-system solution approach and play a key role in supporting the development of new cellular therapies."

Dale Barnhart, President and CEO of Lydall, stated, "I am pleased with the launch of this product family for cellular therapy which represents a strategic growth opportunity. It further demonstrates our commitment to being the global supplier of choice as we grow our presence in this emerging segment."

About Lydall, Inc.

Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, and Germany and offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical and filtration/separation markets. Charter Medical, Ltd., a Lydall subsidiary, is a vital fluids management company focused on providing products to separate, contain and transport vital fluids in the blood and cell therapy market and the biotech and pharmaceutical industries. Lydall(R) is a registered trademark of Lydall, Inc. in the U.S. and other countries. All product names are trademarks of Lydall, Inc. or Charter Medical, Ltd.

Read the original post:
Charter Medical Launches New EXP-Pak(TM) Cell Expansion Containers for Cellular Therapy Applications

Comments are closed.